Completed

NCT Number: NCT01966510

Cord Blood Transplantation in Patients With Advanced Lymphoid Malignancies

Indication: Patients with advanced lymphoid malignancies in the absence of an HLA identical or mismatch donor.

Objectives: Overall survival at one year. Efficacy >60%, rejection rate <20%. Inclusion criteria: Age: 18-65 years old, no sibling or unrelated donor identified, low grade non-hodgkin lymphoma in third line (who already received at least one autologous transplantation); hodgkin lymphoma in early relapse (<1 year), who received at least one autologous transplantation and sensible to chemotherapy and CLL with 17p deletion or in relapse less than 2 year after a fludarabine nbased regimen or in relapse after one autologous transplantation.

Stem cell source: Two cord blood units containing both together more than 3x107 frozen nucleated cells/Kg with no more than 2 out of 6 HLA mismatches between them and with the patients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Patients With Advanced Lymphoid Malignancies in the Absence of an HLA Identical or Mismatch Donor

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Saint Louis hospital

Paris, 75010, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Age: 18-65 years old
no sibling or unrelated donor identified (9/10 or 10/10)
with either one of these advanced lymphoid malignancies

low grade non-hodgkin lymphoma in third line (who already received at least one autologous transplantation)
hodgkin lymphoma in early relapse (<1 year)who received at least one autologous transplantation and sensible to chemotherapy
CLL with 17p deletion or in relapse less than 2 year after a fludarabine nbased regimen or in relapse after one autologous transplantation.

Exclusion criteria

No patient signed consent
Previous allograft
Psychiatric conditions
HIV positive
HVC hepatitis requiring treatment
Previous total body irradiation (TBI)
Any contraindication to TBI
Any contraindication to allograft, such as cardiovascular, respiratory, renla or liver dysfunctions
No Health care insurance

Treatment and study plan